CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cytophage Technologies Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cytophage Technologies Ltd
200A-400 Fort Whyte Way
Phone: (416) 214-4810p:416 214-4810 OAK BLUFF, MB  R4G 0B1  Canada Ticker: CYTOCYTO
Business Summary
Cytophage Technologies Ltd. is a Canadian biotechnology company focused on bacteriophage research, product development and commercialization. The Company’s business activity is to develop bacteriophages that will reduce and ultimately replace the use of antibiotics for illness prevention and treatment. Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defenses. The Company is using de-risked and patented technology to advance products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security. Its products include FarmPhage, AviPhage, PhageFend, and BoviPhage. FarmPhage is a water-soluble phage solution for livestock. AviPhage is a poultry health product offered by the Company.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Thomas G.Wellner 8/1/2025 8/1/2025
Chief Executive Officer, Director StevenTheriault 2/2/2024 2/2/2024
Chief Financial Officer Julius J.Kalcevich 2/2/2024 2/2/2024
6 additional Officers and Directors records available in full report.

Business Names
Business Name
CIII
CIII.P
CYTO

General Information
Outstanding Shares: 61,685,221 (As of 6/20/2025)
Stock Exchange: CVE


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, August 22, 2025